An overview on age related macular degeneration and recent advances in its management

• Main Authors: SOBIA N., SARA F., AYESHA F.
• Format: Article
• Language: English
• Published: Phytochemistry & Organic Synthesis Laboratory 2014-03-01
• Series: PhytoChem & BioSub Journal
• Subjects: age-related macular degeneration; smoking; vascular endothelial growth factor; bevacizumab; pegaptanib; ranibizumab
• Online Access: https://drive.google.com/file/d/0B8ZU6DpsSi6URGNIX1dmRFVTXzQ/view?usp=sharing

Age-related macular degeneration (AMD) is a condition characterized, in the early stages, by slow development and progression, absence of symptoms over a number of years, and extensive retinal deposits called drusen, often associated with pigmentary abnormalities (early AMD).There is strong and consistent evidence that increasing age, family history, obesity/high body mass index, and cataract surgery are associated with late AMD. Smoking is the strongest and most consistently found modifiable risk factor for late AMD.Age-related macular degeneration remains one of the most severe and profound disabilities encountered in medicine, particularly due to the loss of the central vision and the high economic burden it places on patients and societies.Recent advances in management of AMD is anti-angiogenic drugs. The identification of the crucial role played by vascular endothelial growth factor (VEGF) in the pathogenesis of wet AMD hasallowed the development of VEGF-blocking agents such as bevacizumab, pegaptanib and ranibizumab.